Clinical Trials · NCT04251156

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
375
Start date
Dec 2020
Locations
33 sites, 4 countries
Primary endpoint
Change From Baseline in Body Weight (Percentage [%])
View Semaglutide compound reference